News & Updates

Clinical oncology pioneer joins PharmEnable’s board

Clinical oncology pioneer joins PharmEnable’s board

Exciting news at PharmEnable: we are proud to welcome Dr Ian Collins to our board as a new non-executive director. With three decades of experience in drug discovery and drug development, Ian will support our mission to push the boundaries of what is possible in the...

read more
PharmEnable Closes $7.5M Financing led by MP Healthcare

PharmEnable Closes $7.5M Financing led by MP Healthcare

PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases $7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group....

read more
PharmEnable awarded PLG Collaboration Deal of the Year Award

PharmEnable awarded PLG Collaboration Deal of the Year Award

We are delighted that our business development team has been recognised with the prestigious Collaboration Deal of the Year Award by the Pharmaceutical Licensing Group for our shared-risk collaboration with Sosei Heptares, an international biopharmaceutical group. The...

read more
In focus: Unlocking the potential of GPCR targets

In focus: Unlocking the potential of GPCR targets

GPCR representation, the tertiary structure of bovine rhodopsin within the cell membrane (in grey). Source: Wikimedia Commons PharmEnable has recently partnered with Sosei Heptares to work on a challenging G protein-coupled receptor (GPCR) target for a neurology...

read more